Merck & Co. (MRK) announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with paclitaxel for specific types of ovarian cancer. This approval targets adult patients with PD-L1+ platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma. Notably, this marks the first and only PD-1 inhibitor approved for this specific patient population, addressing a significant unmet medical need. The regulatory decision was supported by results from the Phase 3 KEYNOTE-B96 trial, which demonstrated a significant reduction in the risk of disease progression or death. This milestone is expected to strengthen Merck's oncology portfolio and enhance the long-term revenue outlook for its flagship drug. Investors and analysts view this development as a positive driver for the company's market position in the competitive pharmaceutical sector.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis